BUY Aurobindo Pharma — Siddharth Rai Mangala, 21 Sept 2026

bySiddharth Rai MangalaHorizon: NA (inferred Intraday)21 Sept 2026, 12:14 pm ISTvia Zee Business (Live)

Entry₹1,731Inferred

Target₹1,775

Stop loss₹1,699-1.85% risk

At expiry₹1,71221 Sept 2026, 3:05 pm

Expired-1.10%

Follow Siddharth Rai Mangala for new calls(13% target hit, 84 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 1 active Intraday pick this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 21 Sept 2026

6 supporting0 opposing

Supports the BUY call (6)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·21 Sept · today

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 5d ago

Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler

NewsNdtv-Profit·15 Sept · 5d ago

Aurobindo Pharma gets US FDA nod to sell first metered-dose asthma inhaler in US

NewsCnbc-Tv18·15 Sept · 6d ago

Aurobindo Pharma received final US FDA approval for its Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths.

BSE · Company Update·15 Sept · 6d ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.